[205] prepared soluble MN by dissolving hydrophilic antigen and hydrophobic adjuvant Toll-like receptor 7/8 (TLR7/8) agonist (R848) in Pluronic F127 for cancer immunotherapy (Fig. 16). Here, TLR7 is linked to cancer.